Dexcom Inc
F:DC4
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Dexcom Inc
F:DC4
|
US |
|
N
|
Nov Inc
XBER:NO8
|
US |
|
B
|
Baozun Inc
HKEX:9991
|
CN |
|
C
|
Churchill Downs Inc
XMUN:CHR
|
US |
|
N
|
Neo Performance Materials Inc
F:N14
|
CA |
|
R
|
Rigolleau SA
BCBA:RIGO
|
AR |
|
Y
|
Yum China Holdings Inc
HKEX:9987
|
CN |
|
L
|
Levi Strauss & Co
SWB:LV2B
|
US |
|
S
|
Sprott Inc
NYSE:SII
|
CA |
|
A
|
Apollo Medical Holdings Inc
F:3AM
|
US |
|
B
|
Broadstone Net Lease Inc
F:62XA
|
US |
|
JinkoSolar Holding Co Ltd
NYSE:JKS
|
CN |
|
A
|
Ad Pepper Media International NV
XMUN:APM
|
DE |
|
Reckitt Benckiser Group PLC
F:3RB
|
UK |
|
A
|
Arch Resources Inc
SWB:ACCA
|
US |
|
B
|
Bayer AG
XBER:BAYN
|
DE |
|
C
|
Camping World Holdings Inc
SWB:C83
|
US |
|
FirstRand Ltd
OTC:FANDF
|
ZA |
|
M
|
Mandom Corp
F:MD9
|
JP |
|
A
|
Ad Pepper Media International NV
XBER:APM
|
DE |
|
C
|
Cal-Comp Electronics Thailand PCL
SET:CCET
|
TH |
|
G
|
GlaxoSmithKline PLC
F:GS7A
|
UK |
|
Pasco Corp
TSE:9232
|
JP |
|
A
|
Ad Pepper Media International NV
XHAM:APM
|
DE |
Dexcom Inc
Dexcom makes continuous glucose monitoring systems for people with diabetes. Its core product is a small wearable sensor that tracks glucose levels through the day and sends readings to a smartphone, receiver, or insulin pump, so users can manage blood sugar without repeated finger sticks. The company also sells the software and connected apps that display trends and alerts. Its main customers are people with diabetes, along with the doctors, clinics, hospitals, and insurance plans that recommend, prescribe, or reimburse the devices. Dexcom makes money mostly by selling the disposable sensors and other consumables that patients replace regularly, plus related receivers and accessories. That gives the business a recurring revenue pattern rather than a one-time device sale. What makes Dexcom different is that it sits between medical devices and digital health. It does not just make hardware; it sells an ongoing monitoring service built around data, alerts, and software that help patients and caregivers respond quickly to glucose changes. In the diabetes care chain, Dexcom is a key provider of real-time glucose data used to guide daily treatment decisions.
Dexcom makes continuous glucose monitoring systems for people with diabetes. Its core product is a small wearable sensor that tracks glucose levels through the day and sends readings to a smartphone, receiver, or insulin pump, so users can manage blood sugar without repeated finger sticks. The company also sells the software and connected apps that display trends and alerts.
Its main customers are people with diabetes, along with the doctors, clinics, hospitals, and insurance plans that recommend, prescribe, or reimburse the devices. Dexcom makes money mostly by selling the disposable sensors and other consumables that patients replace regularly, plus related receivers and accessories. That gives the business a recurring revenue pattern rather than a one-time device sale.
What makes Dexcom different is that it sits between medical devices and digital health. It does not just make hardware; it sells an ongoing monitoring service built around data, alerts, and software that help patients and caregivers respond quickly to glucose changes. In the diabetes care chain, Dexcom is a key provider of real-time glucose data used to guide daily treatment decisions.
Topline: DexCom reported first-quarter revenue of $1.19 billion, up 15% from a year ago, with organic growth of 12%, driven by broader access, new product launches and active user growth.
Margins: Gross margin improved sharply to 63.5%, and management raised full-year operating margin and EBITDA margin guidance, while keeping revenue guidance unchanged.
U.S. momentum: The company said U.S. share gains were strongest in type 2 diabetes, especially among non-insulin users, helped by broader coverage and the launch of G7 15 Day.
Coverage wins: DexCom announced Prime Therapeutics will begin covering CGM for all people with diabetes this summer, taking commercial coverage for more than 7 million type 2 non-insulin lives by year-end.
Product pipeline: G7 15 Day, a redesigned Stelo app, patch technology and Smart Basal were all highlighted as near-term product drivers and customer-experience upgrades.
Longer-term catalyst: Management expects the randomized trial in type 2 non-insulin patients to be presented at ADA in a few weeks and continues to view CMS coverage expansion as a matter of time.
